Company profile
BioAge Labs, Inc.
NASDAQ:BIOABiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ASAPIPRANT | phase2 | — | 1 | terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07656727 | phase2 | recruiting | 2026-06-11 | 2026-11-30 | BioAge Labs, Inc. | A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors |
| NCT06515418 | phase2 | terminated | 2024-06-27 | 2025-02-06 | BioAge Labs, Inc. | Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over |
| NCT06141889 | phase1 | completed | 2023-11-17 | 2024-01-26 | BioAge Labs, Inc. | Pharmacokinetics Study of Azelaprag (BGE-105) in Older Adult Healthy Volunteers |
| NCT05152641 | phase2 | withdrawn | 2022-04-01 | 2023-04-01 | BioAge Labs, Inc. | Study to Evaluate Efficacy and Safety of BGE-117 in Moderately to Severely Anemic Older Individuals After Major Hip Surgery |
| NCT04815603 | phase2 | withdrawn | 2021-03-22 | 2022-04-01 | BioAge Labs, Inc. | Study to Evaluate Efficacy and Safety of BGE-117 in the Treatment of Anemia of Aging |
FDA applications (0)
No records yet.